Pangaea Data
- Company typePrivate
- Founded2017
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Pangaea Data does
Pangaea Data is a London- and San Francisco-headquartered AI software company founded in 2017 that builds the PALLUX platform, a multimodal AI system designed to analyze structured and unstructured patient data — including clinical records, imaging, genomic information, and real-world data — to identify individuals who are undiagnosed, under-treated, or at elevated clinical risk. The company's core application is surfacing patients with conditions where diagnostic delays are long and underdiagnosis is severe, with the lead use case being Alpha-1 Antitrypsin Deficiency (AATD), where it claims up to 90% of U.S. patients remain undiagnosed despite relevant information already existing in medical records. The platform has expanded into adjacent therapeutic areas including COPD, severe asthma, rare disorders, ophthalmology (glaucoma and diabetic retinopathy via integration with Topcon's Harmony platform), and oncology social drivers of health.
The company operates an enterprise go-to-market in which large pharmaceutical companies and healthcare technology vendors sponsor the configuration and deployment of the platform. Strategic multi-year partnerships with Sanofi (AATD deployment across select U.S. health systems and low-income community clinics) and AstraZeneca (global multimodal AI deployment for clinical decision-making, patient identification, and clinical trial recruitment) anchor the commercial model. Additional relationships include a strategic investment and platform integration from Topcon Healthcare and an academic deployment at the University of Illinois Chicago Cancer Center. Pangaea leverages generative and predictive AI capabilities from Microsoft and NVIDIA rather than positioning itself as a foundation model developer.
The business model is enterprise platform licensing via multi-year, sponsor-funded deployments with undisclosed contract values and custom configuration terms. The company is privately held and venture-backed, with disclosed institutional investors including Ascension, Salica, IQ Capital, and Koa Labs (2021 round), alongside a 2025 strategic investment from Topcon Healthcare. With 11-50 employees, Pangaea is an early-stage, commercially scaling company rather than a mature enterprise software vendor, and its revenue, headcount growth rate, and customer count beyond named logos are not publicly disclosed.
Pangaea Data firmographics
Firmographics- Name
- Pangaea Data
- Legal name
- Pangaea Data
- Website
- https://pangaeadata.ai
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Pangaea Data industry classification
Industry- Product category
- Healthcare AI Software
- NAICS
- Software Publishers (5132)
- SIC
- Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)
- akta.pro secondary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where Pangaea Data is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Pangaea Data business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Enterprise Platform Licensing and Deployment: Multi-year enterprise agreements with pharmaceutical companies and healthcare systems where partners sponsor configuration and deployment of Pangaea's AI platform
Go-to-market motion2 records
Distribution channels3 records
Pangaea Data product offering
Product offeringCore offering
Pangaea Data provides the PALLUX platform, a proprietary AI-driven software that analyzes structured and unstructured patient records in real-time to identify underdiagnosed and untreated patients. The platform integrates clinical, imaging, genomic, and real-world data through multimodal AI capabilities (leveraging Microsoft and NVIDIA technologies) to support clinical decision-making for patient identification, diagnosis, treatment, and connection to therapies or clinical trials across conditions including genetic disorders, respiratory diseases, cancer, and eye health.
Product overview
Pangaea Data offers a unified AI platform for population health management and clinical decision support. The core product, PALLUX, is a proprietary AI platform that analyzes structured and unstructured patient data to identify at-risk individuals, supporting early detection of underdiagnosed conditions. The platform integrates clinical, imaging, genomic, and real-world data to enable multimodal AI capabilities for improving patient identification, diagnosis, and connection to appropriate treatments or clinical trials.
Differentiator
Problem solved
Functional benefit
Products and services
- PALLUX Platform Proprietary AI platform that analyzes structured and unstructured patient records to identify untreated and underdiagnosed patients in real-time, supporting disease detection across multiple therapeutic areas including genetic disorders (e.g., AATD), respiratory conditions (COPD, severe asthma), cancer (SDOH analysis), and eye health (glaucoma, diabetic retinopathy). Designed for pharmaceutical companies, healthcare systems, academic medical centers, and ophthalmology providers.
Quantifiable outcome
- Up to 90% of people with AATD remain undiagnosed in the U.S.
- +1 more outcomes
Companies that use Pangaea Data
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles2 records
Pangaea Data technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability7 records
Feature4 records
Pangaea Data partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- SanoficorePartnership with Sanofi to deploy an AI platform for detecting Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder affecting the lungs and liver. The platform will be distributed across select U.S. healthcare systems and low-income community clinics to identify at-risk individuals in real-time.
- AstraZenecacoreStrategic multi-year partnership with AstraZeneca to deploy multimodal AI in clinical settings. AstraZeneca is sponsoring the configuration and deployment of Pangaea's enterprise platform that integrates clinical, imaging, genomic, and real-world data. The collaboration leverages generative and predictive AI capabilities from Microsoft and NVIDIA to scale AI-driven clinical decision-making for patient identification, diagnosis, treatment, and connection to therapies or clinical trials.
- University of Illinois Chicago Cancer CenterminorPangaea Data's AI platform was adopted by the University of Illinois Chicago Cancer Center to analyze electronic health records and uncover social drivers of health (SDOH) impacting patient outcomes in urologic cancer patients.
- Topcon HealthcarecoreTopcon Healthcare's strategic investment in Pangaea Data's AI platform PALLUX, marking the company's second investment in less than a week as part of its Healthcare from the Eye initiative. The PALLUX platform analyzes patient records to identify untreated and under-treated patients.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
Pangaea Data competitors and assessment
Company assessmentDirect peers
- Tempus AI: AI-driven precision medicine platform that integrates clinical, molecular, and imaging data with pharma partnerships for patient identification and clinical trial recruitment. Closely aligned with Pangaea's multimodal data and pharma-sponsorship model.
- Owkin: AI-for-clinical-research platform with deep pharma partnerships, focused on patient stratification and real-world data analytics. Highly comparable go-to-market and technology stack to Pangaea.
- nference: AI/biomedical informatics platform that derives insights from structured and unstructured clinical data and partners with pharma. Directly comparable multimodal EHR-to-pharma offering.
Broad incumbents
- IQVIA: Largest real-world data and clinical decision support vendor, serving pharma and providers globally. Indirect competitor given breadth, with overlap in RWD-driven patient identification.
- Verily (Alphabet): Clinical data, real-world evidence, and AI-driven care platforms within Alphabet. Comparable multimodal clinical-to-pharma model at greater scale and capital depth.
- Foundation Medicine: Molecular diagnostics and genomic profiling company (Roche) used by pharma for patient identification and clinical trials. Comparable genomics-driven pharma partnership model.
- Flatiron Health: Oncology-focused EHR data and analytics platform (Roche), serving pharma for patient identification and RWD. Comparable in pharma-served real-world clinical data analytics.
Emerging players
- ConcertAI: AI-driven real-world evidence and clinical decision support for oncology, with pharma-sponsored deployments. Comparable in targeting pharma customer base and RWD analytics.
- Arterys: Cloud-native AI medical imaging platform integrated into clinical workflows. Adjacent to Pangaea's imaging-modality capability and clinical decision support positioning.
- DeepHealth (RadNet): AI-powered clinical imaging and workflow platform, with pharma and provider partnerships. Comparable in combining imaging with clinical decision support.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Pangaea Data social profiles
Digital presencePangaea Data financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pangaea Data leadership team
Management profileNumber of profiles
Profiles2 records
Pangaea Data funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pangaea Data M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pangaea Data
What does Pangaea Data do?
Pangaea Data provides the PALLUX platform, a proprietary AI-driven software that analyzes structured and unstructured patient records in real-time to identify underdiagnosed and untreated patients. The platform integrates clinical, imaging, genomic, and real-world data through multimodal AI capabilities (leveraging Microsoft and NVIDIA technologies) to support clinical decision-making for patient identification, diagnosis, treatment, and connection to therapies or clinical trials across conditions including genetic disorders, respiratory diseases, cancer, and eye health.
Is Pangaea Data a public or private company?
Pangaea Data is a private company. It is classified as venture growth investor backed and is currently operating.
When was Pangaea Data founded?
Pangaea Data was founded in 2017. It employs 11 to 50 people.
Where is Pangaea Data based?
Pangaea Data is headquartered in London, United Kingdom, in the Europe region.
How does Pangaea Data make money?
One revenue line is on record: enterprise Platform Licensing and Deployment.
Who are Pangaea Data's main competitors?
Direct peers on record are Tempus AI, Owkin and nference. Broad incumbents are IQVIA, Verily (Alphabet), Foundation Medicine and Flatiron Health. Emerging players are ConcertAI, Arterys and DeepHealth (RadNet).
Does Pangaea Data have an API?
No public API is recorded for Pangaea Data.
What industry is Pangaea Data in?
Pangaea Data's product category is Healthcare AI Software. Its primary akta.pro industry code is HLAGAJAF, Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D), with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 5132 and its SIC code is 8090.